TOMSK, RUSSIA / RankWire.AI / – Russian scientists have evaluated a bioactive coating aimed at enhancing the interaction between titanium orthopedic implants and bone tissue. This material incorporates calcium phosphate derived from hydroxyapatite and contains nitrogen compounds linked with nitric oxide production. Laboratory experiments demonstrated significantly improved survival rates of human mesenchymal stem cells on coated surfaces compared to uncoated titanium. The researchers analyzed the coating’s structure, chemical properties, mechanical strength, and biological response. Their peer-reviewed results were published in Applied Surface Science in 2026.
At Tomsk Polytechnic University, scientists developed the experimental coatings using reactive magnetron sputtering of a hydroxyapatite target within a vacuum chamber. They adjusted the nitrogen and argon gas ratios during deposition to observe how each mixture influenced the resulting surface. The study tested five conditions, from pure nitrogen to pure argon, measuring coating thickness, surface morphology, hardness, wettability, and chemical composition. Additionally, laboratory tests assessed how living human cells responded to the modified titanium surfaces.
Results indicated that the amount of argon affected several physical characteristics of the coatings, with surfaces created in pure argon being denser and harder than those in pure nitrogen. Coating thickness increased alongside the rise in argon proportion. Chemical analysis revealed nitrogen-carbon and nitrogen-oxygen bonds present on the modified surfaces. The team then compared the behavior of human mesenchymal stem cells grown on coated titanium with those on uncoated titanium, focusing on cell viability and markers associated with bone-cell development.
Enhanced cell viability observed in coating tests
The experiments demonstrated that coated surfaces supported significantly higher cell survival than uncoated titanium. After seven days, coatings with greater nitrogen content also suppressed activity in certain genes linked to early bone-cell differentiation. Nevertheless, the cells maintained their capacity for bone formation despite alterations in early gene activity. These effects were studied under controlled laboratory conditions using human mesenchymal stem cells, and the research did not involve testing the coating in patients or evaluating clinical device performance.
The biomedical evaluation was carried out by Immanuel Kant Baltic Federal University and Siberian State Medical University, with additional contributions from Saint Petersburg State University as part of the broader research team. The project was supported by Russia’s national science program. The researchers aimed to identify gas mixtures capable of producing desirable combinations of physical, chemical, and biological coating properties. Hydroxyapatite’s calcium phosphate makeup already finds use in implant coatings because it resembles the mineral component of human bone.
Current research remains within laboratory parameters
The research team has outlined plans for further testing beyond the initial seven-day cell assessment, intending to examine stem cells over periods ranging from 10 to 28 days. They also aim to study the dissolution rate of the coatings and measure nitric oxide release into surrounding tissues in living organisms, although these investigations were not included in the published laboratory results. Presently, the focus remains on coated titanium substrates, material properties, and in vitro cellular responses rather than clinical outcomes in orthopedic patients.
The findings provide comprehensive laboratory data on how different ratios of nitrogen and argon influence calcium phosphate coatings on titanium. Variations in thickness, density, hardness, chemical bonding, and cellular response across the tested gas mixtures were documented. The study also confirmed that coated samples supported higher stem-cell survival than bare titanium under the experimental conditions. However, the research remains in the preclinical phase, and the published experiments do not establish safety or efficacy for human use. Additional biological testing will be necessary to evaluate properties not addressed in the current study.